Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925888 | 0.88 | OPRM1 (0.49) | GAAOPRM1NPC1OPRD1RAB9A | |
| SCHEMBL19926219 | 0.87 | ALDH1A1 (0.58) | GAAOPRM1OPRD1KMT2AMEN1 | |
| SCHEMBL19925898 | 0.85 | ACKR3 (0.47) | GAAOPRM1NPC1OPRD1RAB9A | |
| SCHEMBL19926149 | 0.81 | OPRM1 (0.46) | GAAOPRM1NPC1OPRD1RAB9A | |
| SCHEMBL19925985 | 0.79 | ALDH1A1 (0.39) | NPC1RAB9AALDH1A1 | |
| SCHEMBL19925979 | 0.79 | OPRM1 (0.67) | GAAOPRM1OPRD1KMT2AMEN1 | |
| SCHEMBL19925891 | 0.79 | OPRM1 (0.52) | OPRM1OPRD1KMT2AOPRL1 | |
| SCHEMBL19926292 | 0.77 | OPRM1 (0.45) | GAAOPRM1NPC1OPRD1KMT2A | |
| SCHEMBL30142388 | 0.77 | OPRM1 (0.52) | GAAOPRM1NPC1OPRD1RAB9A | |
| SCHEMBL30142389 | 0.77 | OPRM1 (0.52) | GAAOPRM1NPC1OPRD1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | GAA 1805/4885OPRM1 178/4885NPC1 4038/4885 |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | GAA 1805/4885OPRM1 178/4885NPC1 4038/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | GAA 1805/4885OPRM1 178/4885NPC1 4038/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | GAA 1805/4885OPRM1 178/4885NPC1 4038/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | GAA 1805/4885OPRM1 178/4885NPC1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.